A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients

JHL Biotech

Status and phase: Terminated; Phase 1

Conditions: B Cell Lymphoma

Treatments: Biological: Rituximab; Biological: JHL1101

Study type: Interventional

Funder types: Industry

Identifiers

NCT03670888

JHL-CLIN-1101-02

Details and patient eligibility

About

This is a multicenter, randomized, double-blind, parallel group study to compare the PK, safety, tolerability, immunogenicity and PD of JHL1101 vs Rituxan in subjects with CD20-positive B cell lymphoma. The study duration is 13 weeks. Approximately 128 eligible subjects will be randomized in a 1:1 ratio to receive either JHL1101 (n=64) or Rituxan (n=64). Each subject will receive one intravenous (IV) infusions of the investigational product (IP) at the dose of 375mg/m2 on Day 1. Assessments of PK, safety, tolerability, immunogenicity, PD, and efficacy will be collected over the following 13-week period.

Enrollment: 1 patient

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. CD20-positive B-cell lymphoma.

2. Obtained CR (complete remission) or CRu (uncertain complete remission) after the prior therapy

3. 18 years to 75 years

4. Signed an informed consent

5. Adequate organ function, including the following

   • Absolute neutrophil count (ANC) ≥ 1,500/uL; platelet count ≥ 75,000/uL; hemoglobin ≥ 8 g/dL
   • Total bilirubin ≤ 1.5 times the upper limit of normal (ULN), aspartate transaminase (AST) and/or alanine aminotransferase (ALT) ≤ 2.5 times ULN
   • Serum creatinine ≤ 1.5 times the ULN

6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

7. Chemotherapy: must not have received within 8 weeks of entry onto this study

8. Radiotherapy: must not have received within 4 weeks of entry onto this study

9. Recovery (to baseline or to Grade 1 or less) from prior treatment-related toxicities except alopecia

10. Aagreement to practice contraception

11. More than 6 months life expectancy.

Exclusion criteria

1. Received any investigational drug within 28 days prior to study enrollment
2. Received blood transfusion or any therapies with erythropoietin (EPO), granulocyte-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) within 14 days prior to study enrollment
3. Received previous immunotherapy
4. Received or plan to receive a live vaccine within 28 days of study enrollment
5. Major surgery within 28 days of study enrollment
6. Received systemic steroid therapy with 28 days of study enrollment
7. Received or plan to receive the hematopoietic cell transplant
8. History of gastrointestinal perforation and/or fistula within 6 months prior to study enrollment
9. Known allergic reactions against monoclonal antibody or rituximab.
10. Received rituximab or other anti-CD20 monoclonal antibody
11. Blood concentration of rituximab > 10 ug/mL during screen visit
12. Human immunodeficiency virus (HIV) positive
13. Hepatitis C virus (HCV) antigen and antibody positive
14. Hepatitis B virus surface antigen (HBsAg) positive
15. Body Mass Index (MBI) ≥ 28 kg/m2

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

1 participants in 2 patient groups

JHL1101

Experimental group

Description:

Single dose IV infusion of 375 mg/m2 of JHL1101

Treatment:

Biological: JHL1101

Rituxan

Active Comparator group

Description:

Single dose IV infusion of 375 mg/m2 of Rituximab

Treatment:

Biological: Rituximab